An announcement from Enanta Pharmaceuticals ( (ENTA) ) is now available.
At the Annual Meeting on March 13, 2025, Enanta Pharmaceuticals’ stockholders voted on several key proposals. They re-elected two Class III directors, approved an amendment to the 2019 Equity Incentive Plan to increase shares by 800,000, decided to hold an annual advisory vote on executive compensation, approved the executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for the 2025 fiscal year.
More about Enanta Pharmaceuticals
YTD Price Performance: 18.96%
Average Trading Volume: 540,995
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $141.9M
See more data about ENTA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com